TP53 and B-cell chronic lymphocytic leukemia: As observed in the cell lines, a defect in the antioxidant system allowed the cells to accumulate oxidative damage, as demonstrated by the elevated MDA levels in both single treatments and the combinations, reaching the highest levels in mutant p53 CLL cells treated with PRIMA-1Met plus SAS (Figure 10D).